{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:47:27Z","timestamp":1784166447982,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.pnpbp.2012.10.010","type":"journal-article","created":{"date-parts":[[2012,10,18]],"date-time":"2012-10-18T08:04:55Z","timestamp":1350547495000},"page":"260-266","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Adjunctive effects of aripiprazole on metabolic profiles: Comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs"],"prefix":"10.1016","volume":"40","author":[{"given":"Liang-Jen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Chun","family":"Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Cheng","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2012.10.010_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0010","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.4088\/JCP.v68n1202","article-title":"Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia","volume":"68","author":"Bai","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.014","article-title":"Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study","volume":"111","author":"Bai","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale\u2014revisited","volume":"17","author":"Barnes","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2174\/1568026033452249","article-title":"5-HT2C receptor agonists as potential drugs for the treatment of obesity","volume":"3","author":"Bickerdike","year":"2003","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0030","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbalip.2011.10.002","article-title":"Serum triglycerides and risk of cardiovascular disease","volume":"1821","author":"Boullart","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.v69n0505","article-title":"Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial","volume":"69","author":"Chang","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JCP.0b013e3182485871","article-title":"The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia","volume":"32","author":"Chang","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0045","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/JCP.0b013e31814fb9a3","article-title":"Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients","volume":"27","author":"Chen","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/eje.0.1500715","article-title":"The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors","volume":"150","author":"Choi","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0055","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.pnpbp.2011.03.011","article-title":"Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia","volume":"35","author":"De Risio","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0060","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/JCP.0b013e3181e74555","article-title":"What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?","volume":"30","author":"Deng","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0065","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.pnpbp.2008.02.010","article-title":"Combined antipsychotic treatment involving clozapine and aripiprazole","volume":"32","author":"Englisch","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0070","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0075","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.schres.2008.09.008","article-title":"A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder","volume":"106","author":"Hanssens","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e31819a8dbe","article-title":"Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients","volume":"29","author":"Henderson","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin","volume":"100","author":"Jin","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0269881106068289","article-title":"Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?","volume":"21","author":"Karunakaran","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005053-198506000-00005","article-title":"Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale","volume":"173","author":"Lane","year":"1985","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0115","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.pnpbp.2010.12.003","article-title":"A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone","volume":"35","author":"Lee","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/er.23.2.201","article-title":"Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes","volume":"23","author":"Lewis","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0125","first-page":"CD006629","article-title":"Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems","author":"Mukundan","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0130","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.pnpbp.2004.06.020","article-title":"Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism","volume":"28","author":"Naber","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2012.10.010_bb0140","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2012.10.010_bb0145","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0150","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0155","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bbrc.2006.01.021","article-title":"A negative feedback system between brain serotonin systems and plasma active ghrelin levels in mice","volume":"341","author":"Nonogaki","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0160","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/0269881110368872","article-title":"Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics","volume":"25","author":"Osuntokun","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0165","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","article-title":"Metabolic syndrome with the atypical antipsychotics","volume":"17","author":"Pramyothin","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0180","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 20","key":"10.1016\/j.pnpbp.2012.10.010_bb0185","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0195","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4088\/JCP.v68n0308","article-title":"Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review","volume":"68","author":"Spurling","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","author":"Starrenburg","year":"2009","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0205","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","article-title":"Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study","volume":"64","author":"Takeuchi","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0028-1100425","article-title":"Effects of six second generation antipsychotics on body weight and metabolism \u2014 risk assessment and results from a prospective study","volume":"42","author":"Tschoner","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1359786806071243","article-title":"Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses","volume":"20","author":"Turner","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euroneuro.2011.03.010","article-title":"Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study","volume":"22","author":"Wampers","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb0230","author":"World Health Organization"},{"key":"10.1016\/j.pnpbp.2012.10.010_bb9000","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"284","author":"World Medical Association","year":"2000","journal-title":"JAMA"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584612002655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584612002655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T03:22:52Z","timestamp":1542684172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584612002655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":47,"alternative-id":["S0278584612002655"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2012.10.010","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}